KaloBios Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 44 6,098 20,255 17,712
Cost of Revenue - - - -
Gross Profit 44 6,098 20,255 17,712
Operating Expenses
Research and Development 32,640 24,519 18,512 18,893
Sales, General and Admin. 8,313 5,061 4,010 4,942
Non-Recurring Items - - - -
Other - - - -
Operating Income (40,909) (23,482) (2,267) (6,123)
Income From Continuing Operations
Add'l Income/Expense Items 47 157 35 915
Earnings Before Interest and Tax (40,862) (23,325) (2,232) (5,100)
Interest Expense 1,086 184 - -
Earnings Before Tax (41,948) (23,509) (2,232) (5,100)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (41,948) (23,509) (2,232) (5,100)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (41,948) (23,509) (2,232) (5,100)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (41,948) (23,509) (2,232) (5,100)